Explore more publications!
Djibouti Health Journal
Submit Press Release

Djibouti Health Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Djibouti Health Journal.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on September 2, 2025

electroCore to Participate at H.C. Wainwright Global Investment Conference
September 2, 2025

electroCore to Participate at H.C. Wainwright Global Investment Conference

Indeterminate GlobeNewswire
Krystal Biotech to Present at Cantor Global Healthcare Conference 2025
September 2, 2025

Krystal Biotech to Present at Cantor Global Healthcare Conference 2025

Indeterminate GlobeNewswire
First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI
September 2, 2025

First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI

Indeterminate GlobeNewswire
vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund
September 2, 2025

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

Indeterminate GlobeNewswire
Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter
September 2, 2025

Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

Indeterminate GlobeNewswire
Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025

Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Indeterminate GlobeNewswire
Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference
September 2, 2025

Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference

Indeterminate GlobeNewswire
Replimune Announces Type A Meeting Scheduled with FDA
September 2, 2025

Replimune Announces Type A Meeting Scheduled with FDA

Indeterminate GlobeNewswire
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
September 2, 2025

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire
Catheter Precision Announces Introduction of the LockeT Product Line into Italy
September 2, 2025

Catheter Precision Announces Introduction of the LockeT Product Line into Italy

Indeterminate GlobeNewswire
Stereotaxis to Present at Upcoming Investor Conferences
September 2, 2025

Stereotaxis to Present at Upcoming Investor Conferences

Indeterminate GlobeNewswire
Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
September 2, 2025

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

Indeterminate GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 2, 2025

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism
September 2, 2025

BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism

Indeterminate GlobeNewswire
MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
September 2, 2025

MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress

Indeterminate GlobeNewswire
Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
September 2, 2025

Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism

Indeterminate GlobeNewswire
CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team
September 2, 2025

CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team

Indeterminate GlobeNewswire
Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025
September 2, 2025

Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025

Indeterminate GlobeNewswire
Theratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote “FOR” the Proposed Plan of Arrangement with Future Pak
September 2, 2025

Theratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote “FOR” the Proposed Plan of Arrangement with Future Pak

Indeterminate GlobeNewswire
Theratechnologies annonce que les agences de conseil en vote indépendantes ISS et Glass Lewis recommandent aux actionnaires de voter « EN FAVEUR » du plan d’arrangement prévu avec Future Pak
September 2, 2025

Theratechnologies annonce que les agences de conseil en vote indépendantes ISS et Glass Lewis recommandent aux actionnaires de voter « EN FAVEUR » du plan d’arrangement prévu avec Future Pak

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions